Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab

Clara Aguirre; Virginia Meca-Lallana; Pedro Sánchez; Jose Vivancos

doi:10.1016/j.msard.2019.07.026

Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab

Mult Scler Relat Disord. 2019 Oct:35:270-271. doi: 10.1016/j.msard.2019.07.026. Epub 2019 Aug 6.

Authors

Clara Aguirre¹, Virginia Meca-Lallana², Pedro Sánchez², Jose Vivancos²

Affiliations

¹ Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain. Electronic address: claraguih@hotmail.com.
² Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain.

PMID: 31442904
DOI: 10.1016/j.msard.2019.07.026

Abstract

Alemtuzumab is an anti-CD52 monoclonal antibody approved for the treatment of multiple sclerosis (MS). It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution.

MeSH terms

Adult
Alemtuzumab / therapeutic use*
Cytomegalovirus Infections / complications
Cytomegalovirus Infections / diagnosis*
Female
Humans
Multiple Sclerosis / complications
Multiple Sclerosis / drug therapy*

Substances

Alemtuzumab